Health & Biotech
PharmAust expands studies in NZ, one step closer towards a Phase 3 trial for canine cancer
Health & Biotech
Dr Boreham’s Crucible: Breaking down ASX aspirant Artrya’s AI heart disease warning system
Health & Biotech
ScoPo’s Powerplays: AGM season ‘flushes out negative surprises’ but creates buying opportunities
Health & Biotech
ASX Health Stocks: Cannabis play AusCann commences study of CBD on spinal cord injury
Health & Biotech
ASX Health Stocks: UBI partners with Mayo Clinic, while Medlab jumps 8pc after divestment
Health & Biotech
Check Up: Imagion and Invion both target breast cancer clinical trials
Health & Biotech
Weed Week: Cannabis advent calendars and US Republicans introduce weed bill for veterans
Health & Biotech
‘Delivering in all aspects’: Volpara strengthens and expands as personalised medicines sector leader
Health & Biotech
Creso Pharma ready to move as Republicans ramp up legal cannabis push in US
Health & Biotech
ASX Health Stocks: Pharmaxis jumps 9pc on FDA approval
Health & Biotech
China is about to grant patents like never before, and these ASX stocks have already got some
Health & Biotech
Aegros pockets license from TGA and flags capital raising, as it aims to disrupt the $19bn plasma market
Featured Health & Biotech Stocks
Health & Biotech
Healthcare stocks are as varied as the solutions they are working to solve. The sector covers biotech stocks developing breakthrough pharmaceutical drugs and vaccines to medtech companies launching the latest and greatest medical devices they hope will change the face of healthcare.
Even the ‘budding’ medical cannabis industry is in the mix as researchers explore new applications and treatments.
If you want to know what’s happening with emerging health stocks on the ASX, Stockhead has you covered, with daily stock news, expert insight and research. You can also recap broader industry trends and recent share price movements across the sector in our regular ‘Check Up’ feature.
Accurate, up-to-date news stories are important, especially in the health sector where progress is often slow and risk often high. That’s why we’re focused on helping small cap investors make sense of the medical jargon.